Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine-Reference-Cited by-同舟云学术

Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine

Published:2023-10-05 Issue:1 Volume:65 Page:128-131
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Yasu Takeo¹²³^ORCID,Gando Yoshito¹,Shirota Mikio²³,Kosugi Nobuharu⁴,Kobayashi Masayuki²⁴^ORCID

Affiliation:

1. Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Tokyo, Japan

2. Bokutoh Hospital-Meiji Pharmaceutical University Joint Research Center, Tokyo, Japan

3. Department of Pharmacy, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan

4. Department of Hematology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan

Funder

Japan Society for the Promotion of Science

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2023.2264427

Reference14 articles.

1. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

2. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia

3. Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites

4. AbbVie Inc. VENCLEXTA prescribing information; 2021. [cited 2023 Jun 20]. Available from: https://www. rxabbvie. com/pdf/venclexta. pdf.

5. Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy